Form 8-K - Current report:
SEC Accession No. 0001558370-24-004614
Filing Date
2024-04-02
Accepted
2024-04-02 16:30:20
Documents
15
Period of Report
2024-03-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K krbp-20240328x8k.htm   iXBRL 8-K 47166
2 EX-3.1 krbp-20240328xex3d1.htm EX-3.1 107969
3 EX-10.1 krbp-20240328xex10d1.htm EX-10.1 61866
  Complete submission text file 0001558370-24-004614.txt   380391

Data Files

Seq Description Document Type Size
4 EX-101.SCH krbp-20240328.xsd EX-101.SCH 3403
5 EX-101.LAB krbp-20240328_lab.xml EX-101.LAB 17229
6 EX-101.PRE krbp-20240328_pre.xml EX-101.PRE 10924
19 EXTRACTED XBRL INSTANCE DOCUMENT krbp-20240328x8k_htm.xml XML 5213
Mailing Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054
Business Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054 832-968-4888
Kiromic Biopharma, Inc. (Filer) CIK: 0001792581 (see all company filings)

EIN.: 464762913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39619 | Film No.: 24814746
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)